Biotech Values

[biocqr]

PRTA > Prothena Discontinues Development of NEOD001 for AL Amyloidosis


https://globenewswire.com/news-release/2018/04/23/1485363/0/en/Prothena-Discontinues-Development-of-NEOD001-for-AL-Amyloidosis.html

Based on the results from the Phase 2b PRONTO study, which did not meet its primary or secondary endpoints, the Company asked the independent data monitoring committee (DMC) of the Phase 3 VITAL study to review a futility analysis of the ongoing VITAL study. The DMC recommended discontinuation of the VITAL study for futility. The Company therefore decided to discontinue all development of NEOD001, including the VITAL study as well as the open label extension studies.